Table 1.
Clinical characteristics of OHGS CAD cases and controls.
Table 2.
Linear regression analysis of the relationships between explanatory variables and the level of PCSK9 in the OHGS.
Figure 1.
Mean PCSK9 levels do not differ with atherosclerosis burden.
A Tukey's boxplot displaying PCSK9 levels in OHGS CAD controls (0 diseased vessels) and cases (1, 2 or 3 diseased vessels) in individuals not taking statins. The median is the line in the box, the 1st and 3rd quartiles are the upper and lower edges of the boxes and 1.5 interquartile range (IQR) is displayed as whiskers. Outliers have been removed. (0 vessel disease, N = 280; 1-vessel disease, N = 126; 2-vessel disease, N = 102; 3-vessel disease, N = 104).
Table 3.
Logistic regression analysis of the association of PCSK9 with CAD in the OHGS cohort, stratified by statin use.
Figure 2.
Plasma PCSK9 levels are increased with acute MI.
Numbers in columns reflect sample size per group for individuals not taking a lipid-lowering medication (statin or fibrate) at the time of recruitment. Values are mean±SEM. Asterisks indicate significantly elevated PCSK9 by ANCOVA, p<0.05 after adjusting for variables (age, male sex, BMI, antihypertensive medication use, and smoking) and correcting for multiple comparisons.
Table 4.
Logistic regression analysis of the association of PCSK9 with acute MI in the OHGS cohort, stratified by statin use.
Table 5.
Clinical characteristics of CAD cases and controls from the EmCB sub-study.
Table 6.
Linear regression analysis of the relationships between explanatory variables and the level of PCSK9 in the EmCB sub-study.
Table 7.
Logistic regression analysis of the association of PCSK9 with CAD in the EmCB sub-study.
Table 8.
Logistic regression analysis of the association of PCSK9 with acute MI in the EmCB sub-study.